Detection and sequencing of mutations from clinical specimens is often complicated by the presence of an excess of nonmutated cells. To facilitate the detection and sequencing of minority mutations from clinical specimens, we developed wild-type blocking polymerase chain reaction (WTB-PCR). This technique allows sensitive detection of minority mutations in a tissue sample containing excess wild-type DNA. In WTB-PCR, a nonextendable locked nucleic acid (LNA) oligonucleotide binds tightly to a region of wild-type DNA known to develop point mutations. This LNA sequence blocks amplification of wild-type DNA during PCR while permitting amplification of mutant exon 15. Our results show that the LNA blocking oligonucleotide inhibits amplification of wildtype DNA in a dose-dependent manner. WTB-PCR was able to detect mutant DNA in clinical samples of melanoma tissue containing an excess of nonmelanoma cells. This method was also able to detect small amounts of point mutated or tandem mutated DNA diluted with a much larger concentration of wild-type DNA. This rapid and simple assay overcomes the limitations of current methods to detect minority mutations. The potential applications of WTB-PCR include early diagnosis and prognosis of various cancers.
Detection and sequencing of mutations from clinical specimens is often complicated by the presence of an excess of nonmutated cells. To facilitate the detection and sequencing of minority mutations from clinical specimens, we developed wild-type blocking polymerase chain reaction (WTB-PCR). This technique allows sensitive detection of minority mutations in a tissue sample containing excess wild-type DNA. In WTB-PCR, a nonextendable locked nucleic acid (LNA) oligonucleotide binds tightly to a region of wild-type DNA known to develop point mutations. This LNA sequence blocks amplification of wild-type DNA during PCR while permitting amplification of mutant exon 15. Our results show that the LNA blocking oligonucleotide inhibits amplification of wildtype DNA in a dose-dependent manner. WTB-PCR wasIntroduction Directed therapeutic agents target mutations specific to some cancer cells. The effectiveness of these drugs may be enhanced by assays that determine if the targeted mutation is present in clinical material obtained from an individual patient. However, the pleomorphic nature of most clinical specimens adds obstacles to the development of these assays. Therefore, to facilitate the use of directed therapeutics, we have developed a method to amplify selectively the mutant DNA sequences from clinical samples containing a large excess of wild-type DNA.
Current methods for detecting mutations present in only a small fraction of cells from heterogeneous tissue samples (minority mutations) include laser capture microdissection (LCM) followed by sequencing, allelespecific polymerase chain reaction (AS-PCR), real-time quantitative PCR (Q-PCR), and ligation-based methods. LCM is a powerful approach for isolating pure cell populations from tissue samples. However, the cells of interest must be visibly distinct from the surrounding specimen. Moreover, the method is labor intensive and requires specialized equipment. Q-PCR also requires specialized instrumentation and is limited by probe binding to wild-type templates (Oliver et al., 2000) . AS-PCR is more sensitive than LCM (Miller et al., 2004) but is limited by false positives and its ability to detect only the one mutation targeted by the assay. Moreover, AS-PCR is very sensitive to subtle changes in PCR conditions, which make it difficult to reproduce in different laboratories.
Many ligation-based minority mutation detection methods have been developed. These approaches involve specifically breaking or cutting template DNA at mutation sites due to the presence of a restriction site or base mismatch. Primer oligonucleotide is then ligated to the newly created DNA ends and used to identify mutated DNA by PCR amplification (Makrigiorgos, 2004) . The application of ligation-based methods may be limited by the complexity of the procedure and can also be limited by the error rate of the DNA polymerase used to amplify the limited amount of starting material. In an attempt to overcome the drawbacks of presently available techniques for detecting minority point mutations, we have developed a rapid and simple assay for sequencing mutations in cancer specimens containing an excess of noncancer cells.
Our PCR-based assay utilizes the unique properties of locked nucleic acid (LNA)-substituted oligonucleotides. LNAs are nucleic acid analogs with a 2 0 -O, 4 0 -C methylene bridge. This bicyclic structure locks the ribose moiety into a C3 0 -endo conformation, which significantly increases binding affinity (Tm) (i.e. stabilizes the duplex in A-form conformation) (Latorra et al., 2003) . LNA substituted oligonucleotides bind to natural DNA according to standard base-pairing rules, but with much greater affinity than standard oligonucleotides. The strong affinity of LNA substituted oligonucleotides for complementary sequences results in high melting points. However, a one base mismatch between an LNA oligonucleotide and the complementary strand can lower the melting point 20-301C, thereby allowing an LNA oligonucleotide to discriminate a one base pair difference between templates (Mouritzen, 2003) . For example, a DNA octomer of bases TGCTGGTG has a Tm of 351C, whereas the corresponding LNA octomer exhibits a Tm of 711C. A single base pair mismatch in the DNA octomer decreases Tm by 101C; whereas a single base pair mismatch in the LNA octomer creates a DTm of 261C (Mouritzen, 2003) .
In order to allow LNA-substituted oligonucleotides to block amplification of wild-type DNA, we utilized a mutated form of Taq polymerase, termed the Stoffel fragment, which lacks the 5 0 to 3 0 exonuclease activity that normally hydrolyses blocking DNA strands during primer extension.
We used oncogenic mutations in the kinase domain of the BRAF gene as a prototype mutation 'hotspot' to characterize our method. These mutations are present in about 60% of melanoma specimens with the vast majority occurring within or adjacent to codon 600 (Davies et al., 2002) . We determined the ability of our approach to detect minority point and tandem B-raf mutations in mixtures of mutant and wild-type melanoma cell lines and in clinical specimens containing mixed cell populations.
Results
We designed an LNA-substituted blocking oligonucleotide to inhibit amplification of wild-type B-raf exon 15 while still permitting amplification of the mutant exon. The blocking oligonucleotide was made homologous to a region of the wild-type exon 15 that contains most melanoma B-raf mutations. Three mismatched bases were added to its 3 0 terminus to prevent extension by DNA polymerases. The blocking sequence binds tightly to wild-type exon 15 with a predicted melting point of 731C (SantaLucia, 1998) . However, a single base mismatch in codon 600 would be expected to decrease significantly the blocking sequence's affinity for template. We anticipated that a single base mismatch between the blocking sequence and any of the common 0 -GGCCAAAAATTTAATCAGTGG-3 0 as described by Davies. WTB-PCR was conducted using a Perkin Elmer Cetus (Boston, MA, USA) DNA Thermal Cycler model number 480. Each 100-ml reaction contained 66 ml of distilled H 2 O, 10 ml of 10 Â Stoffel Buffer, 2 ml of dNTP mix (10 mM of each dNTP), 2.5 ml of each flanking primer (32.5 nmol forward and 33.6 nmol reverse), 0.5 ml of AmpliTaq DNA Polymerase Stoffel Fragment, 15 ml of 25 mM MgCl 2 solution, 1 ml of 100 mM LNA blocking sequence, and 1 ml of experimental template. The following sequence was used for the 'blocking' oligonucleotide (LNA bases underlined): 5 0 -GCTA CAGTGAGGG-3 0 . GAPDH control bands were amplified with the following primers: forward: 5 0 -GAAATGTGCTTTGGG GAGGCA-3 0 and reverse: 5 0 -TTTGCAGGGCTGAGTCAGCT TC-3 0 . Touchdown PCR conditions were used to amplify DNA as follows. We denatured our PCR samples at 941C for 2 min, then subjected samples to three sets of three-step cycles with each set running for three cycles. The first set consisted of heating samples to 941C for 30 s, then cooling to 641C for 30 s, and finally reheating to 721C for 45 s. The second set consisted of heating samples to 941C for 30 s, then cooling to 611C for 30 s, and finally reheating to 721C for 45 s. The third set consisted of heating samples to 941C for 30 s, then cooling to 581C for 30 s, and finally reheating to 721C for 45 s. PCR samples were then subjected to 40 three-step cycles of 941C for 30 s, 571C for 30 s, and 721C for 45 s. Final incubation at 701C occurred for 5 min mutations of B-raf exon 15 would reduce the melting point sufficiently to allow amplification of pointmutated exon 15 (Figure 1) .
We tested the ability of our blocking oligonucleotide to prevent primer extension by wild-type Taq polymerase, but found no inhibition of the PCR reaction (Figure 2a) . We hypothesized that the 5 0 -3 0 exonuclease activity of Taq was hydrolysing the LNA component of LNA/DNA double-stranded regions that otherwise would obstruct the enzyme's progress on the template strand. Therefore, in place of full-length Taq, we substituted the Stoffel fragment of Taq, which lacks 5 0 -3 0 exonuclease activity (Yu et al., 1997) . Using the Stoffel fragment polymerase, the blocking oligonucleotide specifically inhibited amplification of wild-type sequence without blocking amplification of a sequence containing a single-point mutation. To determine the minimum concentration of blocker necessary to prevent amplification of genomic DNA containing wild-type B-raf exon 15, we used serial dilutions of the blocking oligonucleotide. As shown in Figure 2b , a minimum of 0.01 nM of blocker was necessary to prevent a visible band in the PCR reaction.
One advantage of wild-type blocking PCR (WTB-PCR) over AS-PCR, for mutation detection, is our method's ability to identify any mutation within the region of the blocking oligonucleotide rather than being limited to one specific point mutation. To illustrate this advantage, we compared the ability of WTB-PCR with AS-PCR to detect mutations in tissue samples and cell lines. Figure 3a shows detection of the T1796A point mutation by both AS-PCR and WTB-PCR in a melanoma tissue sample. Figure 3b shows detection of One chromatograph shows the T1796A point mutation at codon 600 in the A375 cell line, and the other chromatograph shows the TG1796-97AT tandem mutation at codon 600 in the WM266 cell culture line. AS-PCR for the B-raf T1796A mutation was performed using the following primers (LNA base underlined): forward: 5 0 -GGTGATTTTGGTCTAGC TACAAAG-3 0 and reverse: 5 0 -CTATGAAAATACTATAGTT GAGACCTTCAATGA-3 0 . Each reaction was prepared using puReTaq Ready-To-Go PCR beads from Amersham Biosciences (Little Chalfont Buckinghamshire, England). Each 25-ml reaction contained 22 ml of distilled H 2 O, 1 ml of each primer (28.0 nmol forward and 27.79 nmol reverse), and 1 ml of experimental template. GAPDH control bands were amplified with the GADPH primers described above. We preincubated PCR reactions at 941C for 2 min prior to 35 three-step cycles of 941C for 30 s, 521C for 45 s, and 721C for 45 s. B15, Braf Exon 15 flanking primer set this same point mutation by both methods in the A375 cell line, which is homozygous for the point mutation. However, only WTB-PCR is able to detect the TG1796-97AT tandem mutation in the WM266 cell line, which is heterozygous for the tandem mutation. This demonstrates WTB-PCR's ability to detect multiple mutations within exon 15, thereby overcoming the limitation of detecting one specific mutation by AS-PCR.
To determine the ability of our approach to identify minority mutations in a mixture of cell lines, we 'spiked' wild-type genomic DNA with small amounts of genomic DNA containing the mutant B-raf (Figure 4a) . One mixture contained wild-type DNA spiked with T1796A point mutated DNA and another mixture contained wild-type DNA spiked with TG1796-97AT tandem point mutation DNA. The mixture with single-point mutated DNA contained a 100-fold excess of wild-type DNA compared to mutant DNA, whereas the mixture with tandem point mutated DNA contained a 62.5-fold excess of wild-type DNA compared to mutant DNA. WTB-PCR was performed on each of these mixtures with and without the presence of the LNA blocker. Subsequent sequencing of exon 15 yielded wild-type sequences at codon 600 for mixtures with no LNA blocker. Sequencing of mixtures containing the LNA blocker, however, showed mutant sequences at codon 600 despite the excess of wild-type sequence.
To determine the utility of our technique for detecting minority mutations in melanoma specimens containing mixed cell populations, we performed WTB-PCR on genomic DNA extracted from formalin-fixed, paraffin-embedded melanoma tissue sections that morphologically showed an excess of nonmelanoma cells (Figure 4b) . B-raf exon 15 amplified in the presence of blocker shows the T1796A mutant sequence at codon 600 (Figure 4c) , whereas amplification without blocker shows the wild-type sequence at codon 600 (Figure 4d) . Thus, the presence of the LNA blocker during WTB-PCR inhibits amplification of wild-type DNA while allowing amplification of mutant DNA within clinical specimens.
Discussion
The major advantages of mutation detection using WTB-PCR are its simplicity and that its sensitivity is independent of the error rate of the PCR enzyme. WTB-PCR is no more complex or time consuming than standard PCR and requires no additional apparatus. Any approach that uses PCR amplification followed by analysis of the amplified DNA for the presence of mutations will have its sensitivity limited by the frequency of PCR errors (Parsons and Heflich, 1997; Kaur et al., 2002; Liu et al., 2002) . A fundamental advantage of WTB-PCR is that the blocker oligonucleotide prevents amplification of wild-type DNA thereby preventing amplification of any template not containing mutations in the targeted region of the gene. Thus, the sensitivity of the technique is independent of the error rate of the PCR enzyme. WTB-PCR's ability to detect multiple mutations also represents an advantage over previous methods; however, sequencing of amplified DNA is necessary in order to diagnose the particular mutation identified by WTB-PCR.
A previous report used blocking oligonucleotides to improve the target selectivity of PCR reactions (Yu et al., 1997) . However, this study used blocking oligonucleotides composed of natural DNA and therefore required the use of much longer blocking oligonucleotides. This study demonstrated that a natural DNA blocking oligonucleotide could distinguish between two bacterial species by recognizing a region that differed by 17 base pairs. Since LNA binds to complementary DNA with much higher affinity, a much shorter LNA/DNA chimera will have a melting point in the range of temperatures used for PCR. A one base pair mismatch between the LNA blocker and the target DNA will produce a large decrease in melting point since one base pair represents a much larger fraction of the doublestranded region. Therefore, LNA-substituted oligonucleotides provide vastly improved specificity over natural DNA thereby allowing blocking oligonucleotides to identify minority point mutations in clinical samples. Potential applications of WTB-PCR include identification of mutations from formalin-fixed, paraffinembedded specimens containing an excess of wild-type cells, minimal residual disease detection, and identification of cancer cells in blood or body fluids.
